These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35533792)

  • 1. Pharmacokinetic/pharmacodynamic-guided gentamicin dosing in critically ill patients: a revisit of the Hartford nomogram.
    He S; Cheng Z; Xie F
    Int J Antimicrob Agents; 2022 Jun; 59(6):106600. PubMed ID: 35533792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit.
    Xie F; Wang Y; Peng Y; Cheng Z; Li S
    J Antimicrob Chemother; 2021 Aug; 76(9):2335-2341. PubMed ID: 34096596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
    He S; Cheng Z; Xie F
    Drug Des Devel Ther; 2022; 16():13-22. PubMed ID: 35023902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum β-lactamase producing Enterobacterales (ESBL-E).
    Namiki T; Yokoyama Y; Hashi H; Oda R; Jibiki A; Kawazoe H; Matsumoto K; Suzuki S; Nakamura T
    Pharmacotherapy; 2024 Feb; 44(2):149-162. PubMed ID: 37984818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations of Gentamicin Dose Based on Different Pharmacokinetic/Pharmacodynamic Targets for Intensive Care Adult Patients: A Redefining Approach.
    Abbasi MY; Chaijamorn W; Wiwattanawongsa K; Charoensareerat T; Doungngern T
    Clin Pharmacol; 2023; 15():67-76. PubMed ID: 37427084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review.
    Hodiamont CJ; van den Broek AK; de Vroom SL; Prins JM; Mathôt RAA; van Hest RM
    Clin Pharmacokinet; 2022 Aug; 61(8):1075-1094. PubMed ID: 35754071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?
    Udy AA; Lipman J; Jarrett P; Klein K; Wallis SC; Patel K; Kirkpatrick CM; Kruger PS; Paterson DL; Roberts MS; Roberts JA
    Crit Care; 2015 Jan; 19(1):28. PubMed ID: 25632974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Peng Y; Cheng Z; Xie F
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic/pharmacodynamic evaluations of amikacin dosing in critically ill patients undergoing continuous venovenous hemodiafiltration.
    Li S; Zhu S; Xie F
    J Pharm Pharmacol; 2023 Apr; 75(4):515-522. PubMed ID: 36847263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance?
    Ollivier J; Carrié C; d'Houdain N; Djabarouti S; Petit L; Xuereb F; Legeron R; Biais M; Breilh D
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales.
    Asempa TE; Kuti JL; Seroogy JD; Komirenko AS; Nicolau DP
    Clin Ther; 2019 Aug; 41(8):1453-1462. PubMed ID: 31248681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
    Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury.
    Roberts JA; Field J; Visser A; Whitbread R; Tallot M; Lipman J; Kirkpatrick CM
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3635-40. PubMed ID: 20547809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
    De Waele JJ; Lipman J; Akova M; Bassetti M; Dimopoulos G; Kaukonen M; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Udy AA; Starr T; Wallis SC; Roberts JA
    Intensive Care Med; 2014 Sep; 40(9):1340-51. PubMed ID: 25053248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.